通过孟德尔随机化确定的血蛋白质中慢性阻塞性肺病的潜在药物标
Qinyao Jia1, Jiangfeng Xiao2, Wenbo Zhang3,4
1School of Pharmacy, North Sichuan Medical College, Nanchong, China.
BMC pulmonary medicine
|November 25, 2025
概括
这项研究将IL27RA,IL17RD和TIE1基因识别为慢性阻塞性肺病 (COPD) 的潜在治疗标和生物标志物. 需要进一步的研究来证实它们在COPD治疗中的作用.
科学领域:
- 遗传学 遗传学 是一个
- 蛋白质组学是指蛋白质组学.
- 肺部医学 肺部医学
背景情况:
- 慢性阻塞性肺病 (COPD) 是全球主要的死亡原因.
- 目前的COPD治疗有风险,需要更安全,基于机制的疗法.
- 从基因上优先考虑循环蛋白质可以指导新的慢性肺炎治疗和生物标志物发现.
研究的目的:
- 通过基因识别与COPD风险相关的循环蛋白质.
- 为COPD治疗开发和生物标志物发现提名新的蛋白质标.
主要方法:
- 在大型集成等离子体蛋白质组GWAS数据集上利用了两样本的门德尔随机化 (MR).
- 使用FinnGen COPD GWAS进行发现分析和在deCODE和百万退伍军人计划数据集中的复制.
- 使用贝叶斯协同定位,全蛋白质组关联研究 (PWAS) 和蛋白质与蛋白质相互作用 (PPI) 分析的验证结果.
主要成果:
- 在发现分析中确定了11种与COPD风险相关的蛋白质.
- 在分析中,IL27RA和TIE1与COPD风险有着强烈的关联.
- PWAS和PPI分析支持IL27RA,TIE1和IL17RD在功能上与COPD相关.
结论:
- IL27RA,IL17RD和TIE1在遗传学上被提名为COPD治疗研究和生物标志物开发的有前途的候选人.
- 这些发现为未来对COPD的机理学和药理学研究提供了基础.
- 进一步的研究对于将这些遗传发现转化为COPD管理的临床应用至关重要.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
01:22Chronic Obstructive Pulmonary Disease
2.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.2K
01:29Drug Distribution: Plasma Protein Binding
8.3K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.3K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K